Top
Solid Tumors - Healing Genes
1394
post-template-default,single,single-post,postid-1394,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Solid Tumors

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

TCR-engineered T Cells in Solid Tumors (ACTengine)

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Relapsed and/or Refractory Solid Tumors (ACTengine IMA203-101)

Phase 1

DESCRIPTION:

MD Anderson Cancer Center researchers seek patients with solid tumors to trial a new gene-modified stem cell transplant (autologous) which uses a new technology to genetically modify their immune T-cells to attack their tumor. This investigational immunotherapy is customized to the patient.

The treatment will require leukapheresis to collect the T-cells for gene modification, chemotherapy before they are re-infused, and proleukin drugs to help the cells grow. Follow up, including lab and imaging assessments, may continue for up to 12 months.

Line __:

PATIENT MUST:

  • Be 18 years of age or older
  • Have pathologically confirmed advanced and/or metastatic solid tumor
  • Have life expectancy more than 3 months

Line __:

THE STUDY INVOLVES:

  1. Screening to confirm acceptance to the study.
  2. Leukapheresis to collect the patient’s own stem cells, which will be gene-modified in the lab (no treatment during that period) to target cancer cells.
  3. Admission to the study center and a course of chemotherapy.
  4. Infusion of the gene-modified stem cells, followed by aldesleukin/proleukin to promote their growth.
  5. Follow up, including lab and imaging assessments, may continue for up to 12 months.

 

LOCATIONS & CONTACTS:

The study site is at the University of Texas MD Anderson Cancer Center in Houston, TX Map.

Contact:

Jorge Rivas, M.D.  |  346-204-5350  |  [email protected]

 

SPONSORS

Immatics US, Inc.

M.D. Anderson Cancer Center

 

Or go online:

https://clinicaltrials.gov/show/NCT03686124

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader